Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity? - PubMed
- ️Sat Jan 01 2022
Review
Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
Ellen Conceição-Furber et al. Front Endocrinol (Lausanne). 2022.
Abstract
A major challenge of obesity therapy is to sustain clinically relevant weight loss over time. Achieving this goal likely requires both reducing daily caloric intake and increasing caloric expenditure. Over the past decade, advances in pharmaceutical engineering of ligands targeting G protein-coupled receptors have led to the development of highly effective anorectic agents. These include mono-agonists of the GLP-1R and dual GIPR/GLP-1R co-agonists that have demonstrated substantial weight loss in experimental models and in humans. By contrast, currently, there are no medicines available that effectively augment metabolic rate to promote weight loss. Here, we present evidence indicating that activation of the GCGR may provide a solution to this unmet therapeutic need. In adult humans, GCGR agonism increases energy expenditure to a magnitude sufficient for inducing a negative energy balance. In preclinical studies, the glucagon-GCGR system affects key metabolically relevant organs (including the liver and white and brown adipose tissue) to boost whole-body thermogenic capacity and protect from obesity. Further, activation of the GCGR has been shown to augment both the magnitude and duration of weight loss that is achieved by either selective GLP-1R or dual GIPR/GLP-1R agonism in rodents. Based on the accumulation of such findings, we propose that the thermogenic activity of GCGR agonism will also complement other anti-obesity agents that lower body weight by suppressing appetite.
Keywords: G protein-coupled receptor (GPCR); energy balance; glucagon-receptor (GCGR); obesity; weight loss.
Copyright © 2022 Conceição-Furber, Coskun, Sloop and Samms.
Conflict of interest statement
All authors are current or past employees of Eli Lilly and Company.
Figures

Key Discoveries Highlighting the Thermogenic Activity of Glucagon Receptor Agonism Preclinical Models and Man. Glucagon (GCG), energy expenditure (EE), brown adiose tissue (BAT, white adipose tissue (WAT), glucagon-like peptide 1 receptor (GLP-1R).

Schematic representation of the proposed mechanism(s) by which glucagon receptor (GCGR) activation augments metabolic rate and drive weight loss. Glucagon (GCGR)-GCGR agonism contributes to anti-obesity strategies that employ low caloric intake (satiety agents) by augmenting of metabolic rate. Glucagon-GCGR activation increases whole-body energy expenditure by the activation of hepatic futile cycling, and the secretion of thermogenic agents fibrolast growth factor 21 (FGF21) and bile acids (BA) from the liver. Further, GCG-GCGR agonism increases caloric expenditure to protect from obesity, by leveraging the energy wasting activity of uncoupling protein 1 (UCP1) in brown adipose tissue and UCP1-dependent and-independent futile cycling in white adipose tissue. Beta-klotho(KLB), fibroblast growth factor receptor 1 (FGFR1), farnesoid X receptor (FXR), sympahetic nervous system (SNS).
Similar articles
-
Malavazos AE, Iacobellis G, Dozio E, Basilico S, Di Vincenzo A, Dubini C, Menicanti L, Vianello E, Meregalli C, Ruocco C, Ragni M, Secchi F, Spagnolo P, Castelvecchio S, Morricone L, Buscemi S, Giordano A, Goldberger JJ, Carruba M, Cinti S, Corsi Romanelli MM, Nisoli E. Malavazos AE, et al. Eur J Prev Cardiol. 2023 Jun 1;30(8):680-693. doi: 10.1093/eurjpc/zwad050. Eur J Prev Cardiol. 2023. PMID: 36799940
-
Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, Bajrami B, Rist W, Uphues I, Drucker DJ, Klein H, Santhanam R, Hamprecht D, Neubauer H, Augustin R. Zimmermann T, et al. Mol Metab. 2022 Dec;66:101633. doi: 10.1016/j.molmet.2022.101633. Epub 2022 Nov 7. Mol Metab. 2022. PMID: 36356832 Free PMC article.
-
Han C, Sun Y, Yang Q, Zhou F, Chen X, Wu L, Sun L, Han J. Han C, et al. Mol Pharm. 2021 Aug 2;18(8):2906-2923. doi: 10.1021/acs.molpharmaceut.0c00995. Epub 2021 Jul 9. Mol Pharm. 2021. PMID: 34240881
-
Winther JB, Holst JJ. Winther JB, et al. Diabetes Obes Metab. 2024 Sep;26(9):3501-3512. doi: 10.1111/dom.15693. Epub 2024 Jun 9. Diabetes Obes Metab. 2024. PMID: 38853300 Review.
-
Hope DCD, Tan TM. Hope DCD, et al. Peptides. 2023 Apr;162:170962. doi: 10.1016/j.peptides.2023.170962. Epub 2023 Feb 2. Peptides. 2023. PMID: 36736539 Review.
Cited by
-
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.
Folli F, Finzi G, Manfrini R, Galli A, Casiraghi F, Centofanti L, Berra C, Fiorina P, Davalli A, La Rosa S, Perego C, Higgins PB. Folli F, et al. Am J Physiol Endocrinol Metab. 2023 Nov 1;325(5):E595-E609. doi: 10.1152/ajpendo.00236.2023. Epub 2023 Sep 20. Am J Physiol Endocrinol Metab. 2023. PMID: 37729025 Free PMC article. Review.
-
Transforming obesity: The advancement of multi-receptor drugs.
Kusminski CM, Perez-Tilve D, Müller TD, DiMarchi RD, Tschöp MH, Scherer PE. Kusminski CM, et al. Cell. 2024 Jul 25;187(15):3829-3853. doi: 10.1016/j.cell.2024.06.003. Cell. 2024. PMID: 39059360 Review.
-
Incretin and glucagon receptor polypharmacology in chronic kidney disease.
McFarlin BE, Duffin KL, Konkar A. McFarlin BE, et al. Am J Physiol Endocrinol Metab. 2024 Jun 1;326(6):E747-E766. doi: 10.1152/ajpendo.00374.2023. Epub 2024 Mar 13. Am J Physiol Endocrinol Metab. 2024. PMID: 38477666 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous